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the standard cytogenetics classiﬁcation (unfavorable, intermediate,
favorable). We then compared each of this subgroup with the
corresponding population of patients presenting the same risk
factors but owning a HLA identical sibling. In the standard risk
group (n  66), no-donor patients presented a favorable 10-year
survival (74%) compared with patients with a donor (51%) (P 
not signiﬁcant), and allo-SCT should not be recommended. In the
poor risk group (n  131), patients without a donor presented a
poor outcome (10-year OS  17%), which was not better if a
donor existed (28%) (P  .29); in these patients with a poor
outcome whatever the treatment, investigational studies should be
recommended. In the intermediate risk group (n  275), allo-SCT
offered a better outcome; the 10-year probabilities of relapse,
nonrelapse death, OS, and LFS (no donor vs donor) were 47%
versus 18% (P  .0001), 7% versus 17% (P  .02), 47% versus
63% (P  .02), and 45% versus 64% (P  .001), and the 10-year
OS was 56% versus 41% (P  .01). Allo-SCT represent a real
chance of long-term outcome and might beneﬁt from recent ad-
vances. We conclude that long-term outcome might be achieved in
some subgroups of patients and that the indication for allo-ASCT
could be assessed trough a simple classiﬁcation based on common
parameters.
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TOTAL BODY IRRADIATION (TBI) AND G-CSF-COMBINED HIGH-DOSE
CYTARABINE AS A PREPARATIVE REGIMEN FOR ALLOGENEIC HEMA-
TOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOGE-
NOUS LEUKEMIA (AML) AND ADVANCED MYELODYSPLASTIC SYN-
DROME (MDS)
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The most common reason for failure in later-stage patients after
allogeneic hematopoietic stem cell transplantation (allo-HSCT)
for AML and advanced MDS is leukemic relapse, demonstrating
the inability of preparative regimen to completely eradicate leuke-
mic cells. We report the outcome of allo-HSCT for myeloid
malignancies using myeloablative preparative regimen including
TBI and high-dose cytarabine. In addition, granulocyte colony-
stimulating factor (G-CSF) was simultaneously administered with
cytarabine to increase the susceptibility of leukemic cells to cytar-
abine. Patients and Methods: Patients with myeloid malignan-
cies, including AML, AML evolving from MDS, and advanced
MDS (RAEB, RAEB-t, CMML) were eligible. For conditioning,
patients received TBI (12 Gy) followed by intravenous high-dose
cytarabine (3g/m2 every 12 hours for 4 consecutive days). Recom-
binant G-CSF (lenograstim; 5 g/kg/day) was administered intra-
venously by continuous infusion for 4 days, starting 12 hours
before the ﬁrst dose of Ara-C and continued until the last dose of
Ara-C. For the prophylaxis of acute graft-versus-host disease, cy-
closporine A or tacrolimus with or without short-term methotrex-
ate was given. Results: Seventy-nine patients were evaluable, with
a median age of 39 years (range, 15–58 years). Their diagnoses
were AML in 57, AML from MDS in 11, and MDS in 11 (RAEB
in 8, RAEB-t in 1, CMML in 1). Five-year overall survival (OS),
disease-free survival (DFS), and relapse rate (RR) were 79.1%,
76.3%, and 15.2% in AML in remission, and 41.9%, 34.4%, and
46.4% in AML not in remission. These rates were 43.6%, 43.6%,
and 0% in AML from MDS and 71.6%, 72.7%, and 10% in
advanced MDS. For AML in remission, no risk factor affecting OS
and RR was observed, whereas both high-risk karyotype abnormal-
ity and high numbers of blasts in the peripheral blood negatively
affected OS, and these 2 factors and absence of chronic GVHD
signiﬁcantly increased RR in AML not in remission. Conclusions:
These data suggest that TBI and G-CSF combined high-dose
cytarabine is a highly effective regimen for allo-HSCT for AML in
remission, AML evolving from MDS, and advanced MDS with a
notably low incidence of relapse.
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Bollard, C.M.1,3; Straathof, K.C.1; Huls, H.1; Gresik, V.3; Carrum,
G.1,2; Gottschalk, S.1,3; Gee, A.1; Brenner, M.K.1,2,3; Rooney, C.M.1,3;
Heslop, H.E.1,2,3 1. Center for Cell and Gene Therapy, Baylor College of
Medicine, Houston, TX; 2. Methodist Hospital, Houston, TX; 3. Texas
Children’s Hospital, Houston, TX.
EBV-associated Hodgkin’s disease (HD) and some cases of
non-Hodgkins lymphoma (NHL) show type II latency express-
ing the subdominant EBV antigens EBNA1, LMP1, and LMP2,
which may serve as targets for immunotherapy approaches. In
previous studies, we used polyclonal EBV-speciﬁc CTL in pa-
tients with relapsed EBVHD and saw 2 complete and 1 partial
responses in 11 patients. Analyses of EBV-CTL lines showed
that small populations of T cells reactive against the tumor-
associated antigen LMP2 were present in most of the infused
lines, with some expansion in the peripheral blood after infu-
sion. We therefore hypothesized that CTL speciﬁcally targeting
LMP2 might have greater efﬁcacy in these patients. LMP2-
CTLs were generated from 10 patients using dendritic cells and
lymphoblastoid cell lines (LCLs) that had been genetically mod-
iﬁed to overexpress LMP2 by transduction with an
Ad5f35LMP2 vector. Polyclonal LMP2-CTL lines recognized
2–6 (median, 4) LMP2 epitopes, as determined using overlap-
ping LMP2 peptide pools in ELISPOT assays. A mean of 22.8%
(range, 5%-42.1%) of CD8 T cells bound HLA-restricted
LMP2 tetramers, compared with a mean of 0.11% (range,
0.01%-0.24%) of LMP2-tetramer positive CD8 T cells found
in CTLs generated with genetically unmodiﬁed LCLs from the
same patients. So far, 6 patients have been treated with 2 doses
of 2  107 CTL/m2 2 weeks apart. No immediate toxicity was
observed. In patients with identiﬁed LMP2 epitopes, measure-
ment of IFN secretion by CD8 T cells after stimulation with
appropriate LMP2 peptides in ELISPOT assays showed a 4- to
25-fold increase in spot-forming cells after infusions. In con-
trast, frequencies of CMV and superantigen-speciﬁc T cells did
not increase. Four patients without radiologic evidence of dis-
ease who received CTL as adjuvant therapy post-SCT or che-
motherapy remain well up to 12 months post-CTL. Two pa-
tients with measurable disease at the time of CTL infusion had
stable disease 8 weeks post-CTL. They received 2 further doses
of LMP2-CTL. One patient continues with stable disease, and
the other patient had a complete radiologic response. This
patient had a supraclavicular lymph node resection that showed
selective accumulation of LMP2 tetramer-positive cells (0.3%,
compared to 0.01% in the peripheral blood) with few residual
tumor cells. Immunotherapy with autologous LMP2-CTL is
therefore well tolerated in patients with relapsed EBV HD/
NHL, and infused LMP2-CTL cells can localize to the tumor
and induce a clinical response.
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REPAIR OF CROHN’S DISEASE WITH EMBRYONIC STEM CELLS
Feng, Z.; Arrunategui-Correa, V.; Kim, H.S.; Carrier, E. University of
California, San Diego, La Jolla, CA.
The primary objective of this work is to determine differentiation
and repair potential of murine embryonic stem cells (ES) in murine
Crohn’s disease (CD) model. Methods: Colitis was induced in
IL10/ knock-out mice using piroxicam. The colitis in this
model is patchy and progressive and leads to death unless rescue
therapy is provided. Enhanced yellow ﬂuorescent protein (EYFP)
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